Background A feature of glioblastoma (GBM) is cellular and molecular heterogeneity, both
within and between tumors. This variability causes a risk for sampling bias and potential …

The downregulation of specific genes through DNA hypermethylation is a major hallmark of
cancer, although the extent and genomic distribution of hypermethylation occurring within …

Molecular and clinical heterogeneity critically hinders better treatment outcome for
glioblastomas (GBMs); integrative analysis of genomic and epigenomic data may provide …

Glioblastomas are the most common primary central nervous system malignancy tumor in
adults. Glioblastoma patients have poor prognosis, with an average survival period of …

Glioblastoma (GBM) ranks the most common and aggressive primary brain malignant tumor
worldwide. However, the survival rates of patients remain very poor. Therefore, molecular …

Background Gliomas are the most common human brain tumors. Glioblastoma, also known
as glioblastoma multiform (GBM), is the most aggressive, malignant, and lethal glioma. The …

Glioblastoma (GBM) is a most aggressive primary cancer in brain with poor prognosis. This
study aimed to identify novel tumor biomarkers with independent prognostic values in GBMs …

DNA methylation is an epigenetic change to the genome that impacts gene activities without
modification to the DNA sequence. Alteration in the methylation pattern is a naturally …

Purpose Glioblastoma is the most aggressive form of brain tumors. A better understanding of
the molecular mechanisms leading to its evolution is essential for the development of …

In order to find clinically useful prognostic markers for glioma patients' survival, we employed
Monte Carlo Feature Selection and Interdependencies Discovery (MCFS-ID) algorithm on …